在胶质母细胞瘤中使用 NK 细胞疗法时，白细胞介素-21 是不可或缺的。

IF 48.8 1区医学 Q1 CELL BIOLOGY

Cancer Cell Pub Date : 2024-08-12 DOI:10.1016/j.ccell.2024.07.003

引用次数: 0

摘要

胶质母细胞瘤是最常见的脑癌，5 年生存率不到 10%。这种严峻的预后凸显了对新型治疗方法的迫切需求。在本期《癌细胞》（Cancer Cell）杂志上，Shanley 等人1 报告了一种创新的工程策略，它能增强 NK 细胞对胶质母细胞瘤的免疫力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

When playing the NK cell therapy card in glioblastoma, you can’t beat interleukin-21

Glioblastoma is the most common brain cancer, with a 5-year survival rate of less than 10%. This grim prognosis highlights the urgent need for novel therapeutic approaches. In this issue of Cancer Cell, Shanley et al.¹ report an innovative engineering strategy to supercharge NK cell immunity against glioblastoma.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cancer Cell 医学-肿瘤学

CiteScore

55.20

自引率

1.20%

发文量

179

审稿时长

4-8 weeks

期刊介绍： Cancer Cell is a journal that focuses on promoting major advances in cancer research and oncology. The primary criteria for considering manuscripts are as follows: Major advances: Manuscripts should provide significant advancements in answering important questions related to naturally occurring cancers. Translational research: The journal welcomes translational research, which involves the application of basic scientific findings to human health and clinical practice. Clinical investigations: Cancer Cell is interested in publishing clinical investigations that contribute to establishing new paradigms in the treatment, diagnosis, or prevention of cancers. Insights into cancer biology: The journal values clinical investigations that provide important insights into cancer biology beyond what has been revealed by preclinical studies. Mechanism-based proof-of-principle studies: Cancer Cell encourages the publication of mechanism-based proof-of-principle clinical studies, which demonstrate the feasibility of a specific therapeutic approach or diagnostic test.